Abnormal function of monoamine oxidase-A in comorbid major depressive disorder and cardiovascular disease: pathophysiological and therapeutic implications (review)

Area of Science:

• Biochemistry
• Neuroscience
• Cardiology

Background:

• Major depressive disorder (MDD) and cardiovascular disease (CVD) are frequently comorbid, impacting patient outcomes and healthcare costs.
• The underlying shared biological mechanisms connecting MDD and CVD remain incompletely understood.
• Monoamine oxidase-A (MAO-A), an enzyme crucial for catecholamine degradation, is implicated in the pathophysiology of both MDD and CVD.

Purpose of the Study:

• To propose a model highlighting the central role of MAO-A in the comorbidity of MDD and CVD.
• To elucidate shared pathophysiological mechanisms linking these two conditions.
• To explore the therapeutic potential of targeting MAO-A in comorbid MDD and CVD.

Main Methods:

• Review of existing literature on MDD, CVD, and MAO-A.
• Analysis of the role of MAO-A in catecholamine metabolism and its downstream effects.
• Examination of evidence linking MAO-A activity to oxidative stress, platelet activity, and cytokine levels.

Main Results:

• Increased MAO-A activity contributes to the pathophysiology of both MDD and CVD.
• Dysregulation of MAO-A leads to altered noradrenaline turnover, increased oxidative stress, heightened platelet activity, and elevated cytokine levels.
• MAO inhibitors have demonstrated the ability to reverse these deleterious effects.

Conclusions:

• MAO-A plays a significant role in the shared pathophysiology of comorbid MDD and CVD.
• Targeting MAO-A presents a promising therapeutic strategy for managing patients with both conditions.
• Further research into MAO-A inhibitors could lead to novel treatment approaches for this patient population.